A phase II trial of oral panobinostat (LBH589), a no deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis

被引：1
|
作者：
DeAngelo, D. J.
Tefferi, A.
Mesa, R. A.
Paley, C. S.
Wadleigh, M.
Snyder, D.
Ondovik, M. S.
Rine, J.
Bhalla, K. N.
机构：
[1] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mayo Clin Rochester, Rochester, MN USA
[3] Mayo Clin Arizona, Scottsdale, AZ USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] City Hope Natl Med Ctr, Duarte, CA USA
[6] Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS283
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis
    DeAngelo, Daniel J.
    Tefferi, Ayalew
    Fiskus, Warren
    Mesa, Ruben A.
    Paley, Carole S.
    Wadleigh, Martha
    Snyder, David S.
    Begna, Kebede
    Ondovik, Michael S.
    Rine, Jessica
    Bhalla, Kapil N.
    BLOOD, 2010, 116 (21) : 276 - 277
  • [2] A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
    Mascarenhas, John
    Wang, Xiaoli
    Rodriguez, Amelyn
    Xu, Mingjiang
    Gorman, Elaine
    Zhang, Wenyong
    Goldberg, Judith D.
    Najfeld, Vesna
    Hoffman, Ronald
    BLOOD, 2009, 114 (22) : 130 - 131
  • [3] A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, John
    Sandy, Lonette
    Lu, Min
    Yoon, James
    Petersen, Bruce
    Zhang, David
    Ye, Fei
    Newsom, Carrie
    Najfeld, Vesna
    Hochman, Tsivia
    Goldberg, Judith D.
    Hoffman, Ronald
    LEUKEMIA RESEARCH, 2017, 53 : 13 - 19
  • [4] A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, J.
    Marcellino, B. K.
    Lu, M.
    Kremyanskaya, M.
    Fabris, F.
    Sandy, L.
    Mehrotra, M.
    Houldsworth, J.
    Najfeld, V.
    El Jamal, S.
    Petersen, B.
    Moshier, E.
    Hoffman, R.
    LEUKEMIA RESEARCH, 2020, 88
  • [5] A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia
    Mesa, R. A.
    Camoriano, J. K.
    Geyer, S. M.
    Wu, W.
    Kaufmann, S. H.
    Rivera, C. E.
    Erlichman, C.
    Wright, J.
    Pardanani, A.
    Lasho, T.
    Finke, C.
    Li, C. Y.
    Tefferi, A.
    LEUKEMIA, 2007, 21 (09) : 1964 - 1970
  • [6] A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia
    R A Mesa
    J K Camoriano
    S M Geyer
    W Wu
    S H Kaufmann
    C E Rivera
    C Erlichman
    J Wright
    A Pardanani
    T Lasho
    C Finke
    C Y Li
    A Tefferi
    Leukemia, 2007, 21 : 1964 - 1970
  • [7] A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, John
    Lu, Min
    Li, Timmy
    Petersen, Bruce
    Hochman, Tsivia
    Najfeld, Vesna
    Goldberg, Judith D.
    Hoffman, Ronald
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (01) : 68 - 75
  • [8] The Evolving Understanding of Prognosis in Post-Essential Thrombocythemia Myelofibrosis and Post-Polycythemia Vera Myelofibrosis vs Primary Myelofibrosis
    Masarova, Lucia
    Verstovsek, Srdan
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 299 - 307
  • [9] Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement
    Sliwa, Thamer
    Beham-Schmid, Christine
    Burgstaller, Sonja
    Buxhofer-Ausch, Veronika
    Gastl, Guenther
    Geissler, Klaus
    Krauth, Maria
    Krippl, Peter
    Lang, Alois
    Petzer, Andreas
    Woehrer, Stefan
    Woelfler, Albert
    Gisslinger, Heinz
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 (9-10) : 293 - 302
  • [10] Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement
    Thamer Sliwa
    Christine Beham-Schmid
    Sonja Burgstaller
    Veronika Buxhofer-Ausch
    Günther Gastl
    Klaus Geissler
    Maria Krauth
    Peter Krippl
    Alois Lang
    Andreas Petzer
    Stefan Wöhrer
    Albert Wölfler
    Heinz Gisslinger
    Wiener klinische Wochenschrift, 2017, 129 : 293 - 302
12345